scholarly journals Roles of Autophagy Induced by Natural Compounds in Prostate Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-14 ◽  
Author(s):  
V. Naponelli ◽  
A. Modernelli ◽  
S. Bettuzzi ◽  
F. Rizzi
Keyword(s):  
Prostate Cancer ◽  
Natural Compounds ◽  
Current Evidence ◽  
Metabolic Demand ◽  
Potential Implication ◽  
Protein Levels ◽  
Anticancer Effects ◽  
Intracellular Organelles ◽  
Low Toxicity

Autophagy is a homeostatic mechanism through which intracellular organelles and proteins are degraded and recycled in response to increased metabolic demand or stress. Autophagy dysfunction is often associated with many diseases, including cancer. Because of its role in tumorigenesis, autophagy can represent a new therapeutic target for cancer treatment. Prostate cancer (PCa) is one of the most common cancers in aged men. The evidence on alterations of autophagy related genes and/or protein levels in PCa cells suggests a potential implication of autophagy in PCa onset and progression. The use of natural compounds, characterized by low toxicity to normal tissue associated with specific anticancer effects at physiological levelsin vivo, is receiving increasing attention for prevention and/or treatment of PCa. Understanding the mechanism of action of these compounds could be crucial for the development of new therapeutic or chemopreventive options. In this review we focus on the current evidence showing the capacity of natural compounds to exert their action through autophagy modulation in PCa cells.

scholarly journals Dandelion Root and Lemongrass Extracts Induce Apoptosis, Enhance Chemotherapeutic Efficacy, and Reduce Tumour Xenograft Growth In Vivo in Prostate Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Christopher Nguyen ◽  
Ali Mehaidli ◽  
Kiruthika Baskaran ◽  
Sahibjot Grewal ◽  
Alaina Pupulin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Root Extract ◽  
Natural Health Products ◽  
Anticancer Efficacy ◽  
Adjuvant Therapies ◽  
Anticancer Effects ◽  
Health Products ◽  
Xenograft Models ◽  
Pharmaceutical Uses

Many conventional chemotherapies have indicated side effects due to a lack of treatment specificity and are thus not suitable for long-term usage. Natural health products are well-tolerated and safe for consumption, and some have pharmaceutical uses particularly for their anticancer effects. We have previously reported the anticancer efficacy of dandelion (Taraxacum officinale) root and lemongrass (Cymbopogon citratus) extracts. However, their efficacy on prostate cancer and their interactions with standard chemotherapeutics have not been studied to determine if they will be suitable for adjuvant therapies. If successful, these extracts could potentially be used in conjunction with chemotherapeutics to minimize the risk of drug-related toxicity and enhance the efficacy of the treatment. We have demonstrated that both dandelion root extract (DRE) and lemongrass extract (LGE) exhibit selective anticancer activity. Importantly, DRE and LGE addition to the chemotherapeutics taxol and mitoxantrone was determined to enhance the induction of apoptosis when compared to individual chemotherapy treatment alone. Further, DRE and LGE were able to significantly reduce the tumour burden in prostate cancer xenograft models when administered orally, while also being well-tolerated. Thus, the implementation of these well-tolerated extracts in adjuvant therapies could be a selective and efficacious approach to prostate cancer treatment.

scholarly journals Therapeutic Potential of Gnetin C in Prostate Cancer: A Pre-Clinical Study

Nutrients ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3631
Author(s):  
Ketaki Gadkari ◽  
Urvi Kolhatkar ◽  
Rutu Hemani ◽  
Gisella Campanelli ◽  
Qing Cai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Progression ◽  
Cancer Progression ◽  
Therapeutic Potential ◽  
Inhibitory Effects ◽  
Antitumor Effects ◽  
Anticancer Effects ◽  
Potent Inhibition ◽  
Avian Erythroblastosis Virus

Natural stilbenes have gained significant attention in the scientific community owing to their potential anticancer effects against prostate cancer. We recently reported that Gnetin C, a resveratrol (Res) dimer, demonstrated more potent inhibition of metastasis-associated protein 1/v-ets avian erythroblastosis virus E26 oncogene homolog 2 (MTA1/ETS2) axis in prostate cancer cell lines than other stilbenes. In this study, we investigated in vivo antitumor effects of Gnetin C in two doses (50 and 25 mg/kg, i.p.) using PC3M-Luc subcutaneous xenografts and compared these to Res and pterostilbene (Pter). We found that while vehicle-treated mice revealed rapid tumor progression, compounds-treated mice showed noticeable delay in tumor growth. Gnetin C in 50 mg/kg dose demonstrated the most potent tumor inhibitory effects. Gnetin C in 25 mg/kg dose exhibited tumor inhibitory effects comparable with Pter in 50 mg/kg dose. Consistent with the effective antitumor effects, Gnetin C-treated tumors showed reduced mitotic activity and angiogenesis and a significant increase in apoptosis compared to all the other groups. The data suggest that Gnetin C is more potent in slowing tumor progression in prostate cancer xenografts than Res or Pter. Taken together, we demonstrated, for the first time, that Gnetin C is a lead compound among stilbenes for effectively blocking prostate cancer progression in vivo.

scholarly journals MTA1-Dependent Anticancer Activity of Gnetin C in Prostate Cancer

Nutrients ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 2096 ◽  
Author(s):  
Avinash Kumar ◽  
Kshiti Dholakia ◽  
Gabriela Sikorska ◽  
Luis A. Martinez ◽  
Anait S. Levenson
Keyword(s):  
Prostate Cancer ◽  
Intraepithelial Neoplasia ◽  
Inhibitory Effect ◽  
Tumor Aggressiveness ◽  
Therapeutic Approaches ◽  
Anticancer Efficacy ◽  
Anticancer Effects ◽  
And Migration

The overexpression of metastasis-associated protein 1 (MTA1) in prostate cancer (PCa) contributes to tumor aggressiveness and metastasis. We have reported the inhibition of MTA1 by resveratrol and its potent analog pterostilbene in vitro and in vivo. We have demonstrated that pterostilbene treatment blocks the progression of prostatic intraepithelial neoplasia and adenocarcinoma in mouse models by inhibiting MTA1 expression and signaling. In the current study, we investigated the MTA1 targeted anticancer effects of Gnetin C, a resveratrol dimer, in comparison with resveratrol and pterostilbene. Using DU145 and PC3M PCa cells, we found that Gnetin C downregulates MTA1 more potently than resveratrol and pterostilbene. Further, Gnetin C demonstrated significant MTA1-mediated inhibitory effect on cell viability, colony formation, and migration, while showing a more potent induction of cell death than resveratrol or pterostilbene. In addition, we identified Gnetin C-induced substantial ETS2 (erythroblastosis E26 transformation-specific 2) downregulation, which is not only MTA1-dependent, but is also independent of MTA1 as a possible mechanism for the superior anticancer efficacy of Gnetin C in PCa. Together, these findings underscore the importance of novel potent resveratrol dimer, Gnetin C, as a clinically promising agent for the future development of chemopreventive and possibly combinatorial therapeutic approaches in PCa.

scholarly journals In vitro and In vivo Anticancer Effects of the Novel Vitamin E Ether Analogue RRR-α-Tocopheryloxybutyl Sulfonic Acid in Prostate Cancer

2009 ◽  
Vol 15 (3) ◽  
pp. 898-906 ◽  
Author(s):  
Jing Ni ◽  
Tiejun Mai ◽  
See-Tong Pang ◽  
Imranul Haque ◽  
Kaohsing Huang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Vitamin E ◽  
Sulfonic Acid ◽  
The Novel ◽  
Anticancer Effects

scholarly journals Probing Synergistic Targets by Natural Compounds for Hepatocellular Carcinoma

2021 ◽  
Vol 9 ◽  
Author(s):  
Jian Gao ◽  
Zuojing Yin ◽  
Zhuanbin Wu ◽  
Zhen Sheng ◽  
Chao Ma ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Rational Design ◽  
Transcriptional Activity ◽  
Natural Compounds ◽  
Signaling Networks ◽  
Anticancer Effects ◽  
Synergistic Cytotoxicity ◽  
Combination Drugs ◽  
Reduce Tumor Growth

BackgroundDesigning combination drugs for malignant cancers has been restricted due to the scarcity of synergy-medicated targets, while some natural compounds have demonstrated potential to enhance anticancer effects.MethodsWe here explored the feasibility of probing synergy-mediated targets by Berberine (BER) and Evodiamine (EVO) in hepatocellular carcinoma (HCC). Using the genomics-derived HCC signaling networks of compound treatment, NF-κB and c-JUN were inferred as key responding elements with transcriptional activity coinhibited during the synergistic cytotoxicity induction in BEL-7402 cells. Then, selective coinhibitors of NF-κB and c-JUN were tested demonstrating similar synergistic antiproliferation activity.ResultsConsistent with in vivo experiments of zebrafish, coinhibitors were found to significantly reduce tumor growth by 79% and metastasis by 96% compared to blank control, accompanied by anti-angiogenic activity. In an analysis of 365 HCC individuals, the low expression group showed significantly lower malignancies and better prognosis, with the median survival time increased from 67 to 213%, compared to the rest of the groups.ConclusionTogether, NF-κB and c-JUN were identified as promising synergistic inducers in developing anti-HCC therapies. Also, our method may provide a feasible strategy to explore new targeting space from natural compounds, opening opportunities for the rational design of combinational formulations in combatting malignant cancers.

scholarly journals Heme Oxygenase 1 Impairs Glucocorticoid Receptor Activity in Prostate Cancer

2019 ◽  
Vol 20 (5) ◽  
pp. 1006 ◽  
Author(s):  
Daiana Leonardi ◽  
Nicolás Anselmino ◽  
Javier Brandani ◽  
Felipe Jaworski ◽  
Alejandra Páez ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Glucocorticoid Receptor ◽  
Western Blot ◽  
Heme Oxygenase ◽  
Nuclear Translocation ◽  
Heme Oxygenase 1 ◽  
Castration Resistant Prostate Cancer ◽  
Protein Levels ◽  
Pre Treatment

Glucocorticoids are used during prostate cancer (PCa) treatment. However, they may also have the potential to drive castration resistant prostate cancer (CRPC) growth via the glucocorticoid receptor (GR). Given the association between inflammation and PCa, and the anti-inflammatory role of heme oxygenase 1 (HO-1), we aimed at identifying the molecular processes governed by the interaction between HO-1 and GR. PCa-derived cell lines were treated with Hemin, Dexamethasone (Dex), or both. We studied GR gene expression by RTqPCR, protein expression by Western Blot, transcriptional activity using reporter assays, and nuclear translocation by confocal microscopy. We also evaluated the expression of HO-1, FKBP51, and FKBP52 by Western Blot. Hemin pre-treatment reduced Dex-induced GR activity in PC3 cells. Protein levels of FKBP51, a cytoplasmic GR-binding immunophilin, were significantly increased in Hemin+Dex treated cells, possibly accounting for lower GR activity. We also evaluated these treatments in vivo using PC3 tumors growing as xenografts. We found non-significant differences in tumor growth among treatments. Immunohistochemistry analyses revealed strong nuclear GR staining in almost all groups. We did not observe HO-1 staining in tumor cells, but high HO-1 reactivity was detected in tumor infiltrating macrophages. Our results suggest an association and crossed modulation between HO-1 and GR pathways.

ARV-330: Androgen receptor PROTAC degrader for prostate cancer.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 267-267 ◽  
Author(s):  
Taavi K Neklesa ◽  
Meizhong Jin ◽  
Andrew P Crew ◽  
AnnMarie K Rossi ◽  
Ryan R Willard ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Therapeutic Effects ◽  
Preclinical Development ◽  
Protein Levels ◽  
Novel Approach ◽  
Subsequent Degradation ◽  
20 Nm

267 Background: The transition from localized prostate cancer to metastatic disease often involves modulation of the Androgen Receptor (AR). During the disease progression, patients progressing on enzalutamide or abiraterone therapy exhibit amplified AR, increased intra-tumoral androgen production or AR mutations leading to promiscuity to other ligands. Therefore, AR is still the principal driver of the disease. Methods: A novel approach to block AR signaling is to specifically target AR for degradation. To this end, we have developed the PROteolysis TArgeting Chimera (PROTAC) technology that employs hetero-bifunctional small molecules that simultaneously bind VHL E3 ubiquitin ligase and a target of interest (e.g. AR). Due to induced proximity between VHL and AR, an AR PROTAC leads to ubiquitination and subsequent degradation of AR. Results: Our lead AR PROTAC, ARV-330, degrades 92-98% of total AR in all cell lines tested, with 50% degradation concentrations (DC50) < 1nM. AR degradation suppresses the AR-target gene PSA expression, inhibits proliferation, and induces potent apoptosis in VCaP cells with maximal apoptosis observed at 20 nM. While enzalutamide loses its activity in the presence of > 0.5 nM R1881, ARV-330 maintains its activity. In cells containing the ARF876L mutation, enzalutamide is an agonist; however, ARV-330 remains effective. In fact, ARV-330 is able to degrade all clinically relevant AR mutations. ARV-330 exhibits good pharmacokinetic properties, with t1/2 values of several hours and bioavailability of > 80% after sc injection. Treatment of mice with ARV-330, at doses ranging from 0.3 to 10 mg/kg, results in reduction of AR protein levels. The in vitro potency translates into in vivo efficacy, as ARV-330 demonstrates prostate involution in intact mice. In castrated mice implanted with VCaP tumors, ARV-330 shows robust reduction of plasma PSA and blockade of tumor growth. Conclusions: In summary, the AR PROTAC ARV-330 removes AR from prostate cancer cells in a potent manner and produces therapeutic effects as a result. This cellular efficacy has translated into biomarker activity and efficacy in animal models, and ARV-330 is now in preclinical development.

scholarly journals Curcumin against Prostate Cancer: Current Evidence

Biomolecules ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. 1536
Author(s):  
Deborah Termini ◽  
Danja J. Den Hartogh ◽  
Alina Jaglanian ◽  
Evangelia Tsiani
Keyword(s):  
Prostate Cancer ◽  
Tumor Suppressor Genes ◽  
Antimicrobial Properties ◽  
Chemotherapeutic Agents ◽  
In Vivo Studies ◽  
Current Evidence ◽  
Cellular Processes ◽  
Different Cultures

Cancer is a condition characterized by remarkably enhanced rates of cell proliferation paired with evasion of cell death. These deregulated cellular processes take place following genetic mutations leading to the activation of oncogenes, the loss of tumor suppressor genes, and the disruption of key signaling pathways that control and promote homeostasis. Plant extracts and plant-derived compounds have historically been utilized as medicinal remedies in different cultures due to their anti-inflammatory, antioxidant, and antimicrobial properties. Many chemotherapeutic agents used in the treatment of cancer are derived from plants, and the scientific interest in discovering plant-derived chemicals with anticancer potential continues today. Curcumin, a turmeric-derived polyphenol, has been reported to possess antiproliferative and proapoptotic properties. In the present review, we summarize all the in vitro and in vivo studies examining the effects of curcumin in prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document